Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs

British Journal of Clinical Pharmacology

Volumn 53, Issue 2, 2002, Pages 111-122

  Bertilsson, Leif ^a   Dahl, Marja Liisa ^a   Dalén, Per ^a   Al Shurbaji, Ayman ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antidepressants; CYP2D6; Debrisoquine; Neuroleptics; Polymorphism

Indexed keywords

AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; CODEINE; CYTOCHROME P450 2D6; DEBRISOQUINE; DESIPRAMINE; DRUG METABOLIZING ENZYME; ENCAINIDE; FLECAINIDE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; METOPROLOL; MIANSERIN; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PERHEXILINE; PERPHENAZINE; PHENFORMIN; RISPERIDONE; THIORIDAZINE; TOLTERODINE; UNINDEXED DRUG; VENLAFAXINE; ZUCLOPENTHIXOL;

ALLELE; CATALYSIS; CHROMOSOME 22; DEPRESSION; DNA POLYMORPHISM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG INDUCED DISEASE; DRUG METABOLISM; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE DUPLICATION; GENE FREQUENCY; GENE LOCATION; GENE MUTATION; GENETIC CODE; GENETIC VARIABILITY; HUMAN; MOLECULAR GENETICS; PERIPHERAL NEUROPATHY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; VERTIGO;

ALLELES; CYTOCHROME P-450 CYP2D6; GENE AMPLIFICATION; GENE DUPLICATION; HUMANS; POLYMORPHISM, GENETIC; PSYCHOTROPIC DRUGS;

EID: 0036204756     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01548.x     Document Type: Review

References (87)

1. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds
2. Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy
3. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man
4. Interethnic differences is drug disposition and effects
5. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
6. Pharmacogenomics: Translating functional genomics into rational therapeutics
7. Clinical Review. Pharmacogenetics
8. Pharmacogenetics and adverse drug reactions
9. Polymorphic hydroxylation of debrisoquine in man
10. Polymorphic hydroxylation of debrisoquine in man
11. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
12. Polymorphic oxidation of sparteine and debrisoquine. Related pharmacogenetic entities
13. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
14. The genetic polymorphism of debrisoquine/sparteine metabolism - Clinical aspects
15. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin
16. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations
17. Metoprolol oxidation polymorphism in a Korean population, comparison with native Japanese and Chinese populations
18. Chromosomal assignment of human cytochrome P450 (debrisoquine/sparteine type) to chromosome 22
19. Two mutant alleles of the human cytochrome P450 dbl gene (P450, II, D1) associated with genetically deficient metabolism of debrisoquine and other drugs
20. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteinepolymorphism
21. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification
22. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6
23. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population
24. Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: Polymorhism in RFLP and DNA sequence of CYP2D6
25. Genetic analysis of the Chinese CYP2D locus. Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation
26. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotype in a Korean population
27. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity
28. Decreased capacity for debrisoquine metabolism among black Tanzanians. Analyses of the CYP2D6 genotype and phenotype
29. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population
30. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles
31. Inherited amplification of an active gene in the cytochrome P450 CYP2D-locus as a cause of ultrarapid metabolism of debrisoquine
32. Extremely rapid hydroxylation of debrisoquine - A case report with implication for treatment with nortriptyline and other tricyclic antidepressants
33. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
34. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis
35. Cytochrome P450 2D6 variants in a Caucasian population, allele frequencies and phenotypic consequences
36. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
37. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population
38. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxy risperidone
39. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians
40. E- and Z-hydroxylation of nortriptyline in man - Relationship to polymorphic hydroxylation of debrisoquine
41. 10-Hydroxylation of nortriptyline in Caucasians with 0, 1, 2, 3 and 13 functional CYP2D6 genes
42. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: Relationship to the CYP2D6 genotype
43. Pharmacokinetics of nortriptyline in man after single and multiple oral doses: The predictability of steady-state plasma concentration from single-dose plasma level
44. Nonlinear kinetics of nortriptyline in every day practice
45. Nonlinear kinetics of nortriptyline in relation to nortriptyline clearance as observed during therapeutic drug monitoring
46. Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline
47. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes
48. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: Impact of CYP2D6 genotype on the hydroxylation of nortriptyline
49. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: Clinical implication
50. Clinical pharmacology of antidepressant drugs: Pharmacogenetics
51. The relationship between paroxetine and the sparteine oxidation polymorphism
52. Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers
53. Venlafaxine oxidation in vitro is catalyzed by CYP2D6
54. O- and N-desmethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effects of metabolic inhibitors and SSRI antidepressants
55. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans
56. Venlafaxine serum levels and CYP2D6 genotype
57. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population
58. Haloperidol disposition is dependent of debrisoquine hydroxylation phenotype
59. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor metabolizers
60. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate
61. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients
62. Effects of the CYP2D6* 10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia
63. Plasma concentrations of haloperidol are related to the CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients
64. Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders
65. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol
66. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism
67. Influence of CYP2D6 genetic polymorphism on ratios of steady-state serum concentrations to dose of the neuroleptic zuclopenthixol
68. Maintenance therapy of schizophrenic outpatients with zuclopenthixol decanoate: Associations between plasma zuclopenthixol concentrations, extrapyramidal side-effects, tardive dyskinesia and CYP2D6 genotype
69. Pharmacokinetics of perhexilene maleate in anginal patients with and without peripheral neuropathy
70. Impaired oxidation of debrisoquine in patients with perhexilene neuropathy
71. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism. Screening costs and influence on clinical outcomes in psychiatry
72. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia
73. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype
74. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients
75. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia
76. Genetic association analysis between CYP2D6*2 allele and tardive dyskinesia in schizophrenic patients
77. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes
78. CYP2D6 mutations and therapeutic outcome in schizophrenic patients
79. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients
80. Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness
81. Antiarrythmic activity of the O-desmethyl metabolite of encaidine
82. Clinical implications of variable antiarrythmic drug metabolism
83. Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmacokinetic consequences
84. The genetic polymorphism of debrisoquine/sparteine metabolism - Clinical aspects
85. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tokerodine
86. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population
87. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6